PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24790350-8 2007 PRL response to TRH was normal and levodopa suppressed the increased basal PRL level. Levodopa 35-43 prolactin Homo sapiens 75-78 17590551-0 2008 A case of 6-pyruvoyl-tetrahydropterin synthase deficiency demonstrates a more significant correlation of L-Dopa dosage with serum prolactin levels than CSF homovanillic acid levels. Levodopa 105-111 prolactin Homo sapiens 130-139 17590551-4 2008 Here, we present a case of PTPS deficiency which showed a more significant correlation of dosage of L-Dopa/carbidopa with serum prolactin levels than with CSF HVA levels. Levodopa 100-106 prolactin Homo sapiens 128-137 29427634-3 2018 L-dopa is a natural inhibitor of prolactin (PRL) hormone which is required to maintain lactation in women but it"s over production (hyperprolactinemia) plays critical role in advancement of breast cancer. Levodopa 0-6 prolactin Homo sapiens 33-42 29427634-3 2018 L-dopa is a natural inhibitor of prolactin (PRL) hormone which is required to maintain lactation in women but it"s over production (hyperprolactinemia) plays critical role in advancement of breast cancer. Levodopa 0-6 prolactin Homo sapiens 44-47 17590551-8 2008 On the other hand, even in this relatively small dosing range, the serum prolactin level showed significant negative correlation with the dosage of L-Dopa/carbidopa (R=0.645, p=0.023). Levodopa 148-154 prolactin Homo sapiens 73-82 17590551-10 2008 From these results, we suggest that the serum prolactin level may be a more sensitive marker than the CSF HVA level to guide the dose adjustment of L-Dopa/carbidopa in the management of patients with PTPS deficiency. Levodopa 148-154 prolactin Homo sapiens 46-55 12420085-6 2002 Baseline PRL values were significantly lower for patients with IPD than for those with MSA, both for levodopa-treated and naive patients ( p < 0.004, estimated decrease 55.1 %, 95 % CI from 29.4 % to 71.52 %). Levodopa 101-109 prolactin Homo sapiens 9-12 16544004-6 2005 After treatment with carbidopa/L-dopa, basal TSH (1.6 microU/mL) and Prl (34 ng/mL) decreased and the response to TRH was partially blocked (10.3 microU/mL and 61 ng/mL, respectively). Levodopa 31-37 prolactin Homo sapiens 69-72 11880864-0 2002 Effect of bicalutamide therapy on prolactin response to L-dopa in metastatic prostate cancer patients. Levodopa 56-62 prolactin Homo sapiens 34-43 11880864-12 2002 Moreover, bicalutamide therapy significantly reduced PRL increase in response to L-dopa. Levodopa 81-87 prolactin Homo sapiens 53-56 11880864-1 2002 OBJECTIVES: The secretion of prolactin (PRL), which is a growth factor for prostate cancer cell proliferation, has been proven to present profound alterations in advanced prostate cancer patients, consisting of abnormally elevated baseline levels and paradoxical response to L-dopa. Levodopa 275-281 prolactin Homo sapiens 29-38 11880864-1 2002 OBJECTIVES: The secretion of prolactin (PRL), which is a growth factor for prostate cancer cell proliferation, has been proven to present profound alterations in advanced prostate cancer patients, consisting of abnormally elevated baseline levels and paradoxical response to L-dopa. Levodopa 275-281 prolactin Homo sapiens 40-43 10584673-5 1999 In patients with MSA, basal levels of prolactin were elevated (21.1 +/- 5.2 ng/mL [mean +/-standard error]) compared with control subjects (12.1 +/- 1.7, p <0.05), and after L-dopa there was increased variability in prolactin response with less suppression compared with control subjects. Levodopa 174-180 prolactin Homo sapiens 38-47 10765095-0 2000 Paradoxical stimulation of prolactin secretion by L-dopa in metastatic prostate cancer and its possible role in prostate-cancer-related hyperprolactinemia. Levodopa 50-56 prolactin Homo sapiens 27-36 10765095-4 2000 This study was carried out to analyze PRL secretion in metastatic prostate cancer patients both at basal conditions and in response to L-Dopa and metoclopramide, which represents the most classical inhibitory and stimulatory tests for PRL secretion, respectively. Levodopa 135-141 prolactin Homo sapiens 38-41 10765095-6 2000 On separate occasions, PRL secretion was evaluated in response to L-Dopa (500 mg orally) and to metoclopramide (10 mg i.v. Levodopa 66-72 prolactin Homo sapiens 23-26 10765095-11 2000 CONCLUSION: By showing a paradoxical stimulatory effect of L-Dopa on PRL secretion and a lack of response to metoclopramide in some patients, this study would suggest the existence of evident alterations in the neuroendocrine regulation of PRL release in advanced prostate cancer. Levodopa 59-65 prolactin Homo sapiens 69-72 8867520-5 1996 At the beginning of the study, basal hormonal levels were within normal limits, and levodopa administration induced a significant suppression in PRL and TSH levels (both p < 0.01)) and a significant increase in GH (p < 0.01). Levodopa 84-92 prolactin Homo sapiens 145-148 9545000-8 1998 Conventional treatment of BH4 deficiency, i.e. BH4, 5-hydroxytryptophan, and L-DOPA/carbidopa (the last named given in three doses per day), suppresses prolactin levels merely for a few hours. Levodopa 77-83 prolactin Homo sapiens 152-161 9545000-9 1998 L-DOPA/carbidopa given at shorter intervals or, even better, as a slow release preparation, is more effective in suppressing prolactin levels. Levodopa 0-6 prolactin Homo sapiens 125-134 9545000-12 1998 Treatment with an L-DOPA/carbidopa slow release preparation produces virtually normal prolactin levels. Levodopa 18-24 prolactin Homo sapiens 86-95 9639745-0 1997 [Responses of growth hormone and prolactin to L-Dopa in women with polycystic ovarian syndrome]. Levodopa 46-52 prolactin Homo sapiens 33-42 9639745-2 1997 METHODS: Responses of GH and PRL to L-Dopa (L-DA) (500 mg) were observed in two PCOS groups (LH/FSH > or = 3, Group I, n = 15, LH/FSH < 3, Group II, n = 15) and the control (n = 20). Levodopa 36-42 prolactin Homo sapiens 29-32 9639745-2 1997 METHODS: Responses of GH and PRL to L-Dopa (L-DA) (500 mg) were observed in two PCOS groups (LH/FSH > or = 3, Group I, n = 15, LH/FSH < 3, Group II, n = 15) and the control (n = 20). Levodopa 44-48 prolactin Homo sapiens 29-32 9639745-3 1997 RESULTS: Significantly lower GH (P < 0.01) and higher PRL levels (P < 0.05 in group I) in the basal state, and lower responses of GH and PRL to L-DA were found in two PCOS groups as compared with the control. Levodopa 150-154 prolactin Homo sapiens 143-146 9639745-4 1997 CONCLUSION: The altered basal levels and blunted L-DA evoked responses of GH and PRL suggest a relative decrease of the dopaminergic activity in PCOS patients. Levodopa 49-53 prolactin Homo sapiens 81-84 10774572-11 1999 In addition, by showing a paradoxical rise of PRL in response to L-dopa, which inhibits PRL secretion in physiological conditions, this study would suggest that breast cancer-related hyperprolactinemia may depend at least in part on endogenous disease-related neuroendocrine alterations. Levodopa 65-71 prolactin Homo sapiens 46-49 10774572-11 1999 In addition, by showing a paradoxical rise of PRL in response to L-dopa, which inhibits PRL secretion in physiological conditions, this study would suggest that breast cancer-related hyperprolactinemia may depend at least in part on endogenous disease-related neuroendocrine alterations. Levodopa 65-71 prolactin Homo sapiens 88-91 1518496-1 1992 In this study, on the basis of the inhibiting action of l-dopa administration on prolactin (PRL) secretion, we evaluated in a number of short children the levels of PRL during the provocative stimuli test with l-dopa in order to identify an index able to give reliability to the test and to investigate whether some differences may exist among the subjects showing a different response in growth hormone (GH) secretion to l-dopa. Levodopa 210-216 prolactin Homo sapiens 165-168 7638039-4 1994 Nadir plasma PRL levels during levodopa tests were significantly increased before and during treatment. Levodopa 31-39 prolactin Homo sapiens 13-16 1518496-0 1992 [The effects of l-dopa administration on the prolactin levels in short-stature subjects]. Levodopa 16-22 prolactin Homo sapiens 45-54 1518496-1 1992 In this study, on the basis of the inhibiting action of l-dopa administration on prolactin (PRL) secretion, we evaluated in a number of short children the levels of PRL during the provocative stimuli test with l-dopa in order to identify an index able to give reliability to the test and to investigate whether some differences may exist among the subjects showing a different response in growth hormone (GH) secretion to l-dopa. Levodopa 56-62 prolactin Homo sapiens 81-90 1518496-1 1992 In this study, on the basis of the inhibiting action of l-dopa administration on prolactin (PRL) secretion, we evaluated in a number of short children the levels of PRL during the provocative stimuli test with l-dopa in order to identify an index able to give reliability to the test and to investigate whether some differences may exist among the subjects showing a different response in growth hormone (GH) secretion to l-dopa. Levodopa 56-62 prolactin Homo sapiens 92-95 1518496-1 1992 In this study, on the basis of the inhibiting action of l-dopa administration on prolactin (PRL) secretion, we evaluated in a number of short children the levels of PRL during the provocative stimuli test with l-dopa in order to identify an index able to give reliability to the test and to investigate whether some differences may exist among the subjects showing a different response in growth hormone (GH) secretion to l-dopa. Levodopa 56-62 prolactin Homo sapiens 165-168 1518496-1 1992 In this study, on the basis of the inhibiting action of l-dopa administration on prolactin (PRL) secretion, we evaluated in a number of short children the levels of PRL during the provocative stimuli test with l-dopa in order to identify an index able to give reliability to the test and to investigate whether some differences may exist among the subjects showing a different response in growth hormone (GH) secretion to l-dopa. Levodopa 210-216 prolactin Homo sapiens 165-168 8772480-3 1996 To determine whether the PRL elevation was due to a decrease in hypothalamic generation of DA, we measured the inhibition of PRL by L-dopa before and after inhibition of peripheral decarboxylase activity with carbidopa. Levodopa 132-138 prolactin Homo sapiens 125-128 8772480-4 1996 Without verapamil, L-dopa alone and carbidopa-L-dopa caused similar maximum decreases in PRL levels of 83.2 +/- 2.5 and 80.3 +/- 2.0%, respectively. Levodopa 19-25 prolactin Homo sapiens 89-92 8772480-5 1996 With verapamil, the PRL maximum decrement with L-dopa was 85.2 +/- 2.7% and with carbidopa-L-dopa was 76.3 +/- 1.9% (P < 0.01). Levodopa 47-53 prolactin Homo sapiens 20-23 8836934-6 1996 As expected, LD/carbidopa increased the concentration of GH and decreased that of PRL. Levodopa 13-15 prolactin Homo sapiens 82-85 7638039-6 1994 Peak plasma PRL levels during TRH tests and nadir plasma PRL levels during levodopa tests were also significantly increased. Levodopa 75-83 prolactin Homo sapiens 57-60 1332473-0 1992 Effects of calcium channel blockade with verapamil on the prolactin responses to TRH, L-dopa, and bromocriptine. Levodopa 86-92 prolactin Homo sapiens 58-67 1332473-6 1992 In these same volunteers, PRL levels decreased from 13.2 +/- 2.5 ng/ml to a nadir of 5.5 +/- 1.6 ng/ml in response to L-dopa. Levodopa 118-124 prolactin Homo sapiens 26-29 1332473-8 1992 The percentage decreased in PRL in response to L-dopa (60 +/- 5% versus 62 +/- 3%) were not significantly different (p > 0.05). Levodopa 47-53 prolactin Homo sapiens 28-31 1518496-5 1992 PRL levels significantly decreased in all groups, also in those with a deficient response to l-dopa (1 and 2a); furthermore no significant correlation between PRL and GH levels was demonstrated. Levodopa 93-99 prolactin Homo sapiens 0-3 1842116-5 1991 After TRH, prolactin levels increased to 13.8 ng/ml in controls and 15.2 ng/ml in patients treated with levo-DOPA. Levodopa 104-113 prolactin Homo sapiens 11-20 1842116-7 1991 We postulate that low basal levels of prolactin in patients treated with levo-DOPA reveal a residual suppressing effect of the drug. Levodopa 73-82 prolactin Homo sapiens 38-47 2511222-8 1989 The mean decrement in serum PRL level after L-dopa ingestion was greater in group 1 than in group 3 (P less than 0.05). Levodopa 44-50 prolactin Homo sapiens 28-31 2559014-3 1989 The administration of L-dopa produced a decrease of serum prolactin in all. Levodopa 22-28 prolactin Homo sapiens 58-67 1674920-4 1991 Br or L-Dopa was considered to be effective when serum GH or PRL levels were suppressed more than 50% of the basal value. Levodopa 6-12 prolactin Homo sapiens 61-64 1674920-10 1991 In contrast to the difference in the response of GH, serum PRL level was equally suppressed by Br or L-Dopa in each group. Levodopa 101-107 prolactin Homo sapiens 59-62 2291808-0 1990 Prolactin release and milk removal induced by suckling and milking in lactating ewes is prevented by L-dopa treatment. Levodopa 101-107 prolactin Homo sapiens 0-9 2291808-7 1990 The inhibitory effect of 200 mg of L-DOPA on the secretion of prolactin after milking lasted for about 120 min, and thereafter a significant increase in serum prolactin level occurred. Levodopa 35-41 prolactin Homo sapiens 62-71 2291808-7 1990 The inhibitory effect of 200 mg of L-DOPA on the secretion of prolactin after milking lasted for about 120 min, and thereafter a significant increase in serum prolactin level occurred. Levodopa 35-41 prolactin Homo sapiens 159-168 2291808-9 1990 Doses of 25 or 50 mg of L-DOPA prevented the surge of prolactin observed immediately after milking, but a long-lasting release of prolactin was obtained thereafter. Levodopa 24-30 prolactin Homo sapiens 54-63 2291808-10 1990 The inhibitory effect of L-DOPA on prolactin release could be overridden by the suckling or milking stimuli according to the dose administered. Levodopa 25-31 prolactin Homo sapiens 35-44 3123284-5 1987 The plasma PRL responses to dopaminergic agents (L-dopa, CB-154, dopamine) were greater in responders than in non-responders (% of basal: L-dopa, 33.7 +/- 3.7% vs 51.6 +/- 5.6% at 150 min, P less than 0.05; CB-154, 16.5 +/- 2.6% vs 30.9 +/- 2.8% at 6 hr, P less than 0.05; dopamine, 31.7 +/- 5.6% vs 44.9 +/- 4.3% at 90 min, P less than 0.05). Levodopa 49-55 prolactin Homo sapiens 11-14 2839820-3 1988 The use of L-dopa reducing the levels of ACTH and prolactin led to the improvement of indices of cellular immunity and the patients" clinical status. Levodopa 11-17 prolactin Homo sapiens 50-59 2503796-14 1989 Administration of L-dopa decreased the serum PRL of subject 1 from 33 to 7 ng/mL, but had no clinically significant effect in subject 2. Levodopa 18-24 prolactin Homo sapiens 45-48 2830786-2 1988 Prolactin (PRL) secretory dynamics were evaluated by several stimulation (thyrotropin-releasing hormone [TRH], sulpiride) and suppression (L-dopa) tests. Levodopa 139-145 prolactin Homo sapiens 0-9 2830786-5 1988 L-dopa administration resulted in normal PRL suppression. Levodopa 0-6 prolactin Homo sapiens 41-44 3119696-1 1987 We have investigated the importance of the dopaminergic control of gonadotropin secretion by studying LH, FSH and PRL responses to L-dopa and bromocriptine in patients with polycystic ovary syndrome (PCOS). Levodopa 131-137 prolactin Homo sapiens 114-117 3119696-5 1987 Prolactin sensitivity to the inhibitory effect of bromocriptine and L-dopa showed a significant correlation with the basal PRL level (p less than 0.01). Levodopa 68-74 prolactin Homo sapiens 123-126 3123284-5 1987 The plasma PRL responses to dopaminergic agents (L-dopa, CB-154, dopamine) were greater in responders than in non-responders (% of basal: L-dopa, 33.7 +/- 3.7% vs 51.6 +/- 5.6% at 150 min, P less than 0.05; CB-154, 16.5 +/- 2.6% vs 30.9 +/- 2.8% at 6 hr, P less than 0.05; dopamine, 31.7 +/- 5.6% vs 44.9 +/- 4.3% at 90 min, P less than 0.05). Levodopa 138-144 prolactin Homo sapiens 11-14 3122863-1 1986 Plasma prolactin and GH responses following TRH, sulpiride, L-dopa, and bromocriptine administration. Levodopa 60-66 prolactin Homo sapiens 7-16 3106726-7 1987 Chlorpromazine injections failed to elevate serum prolactin in all patients, and administration of levodopa caused a partial reduction in serum prolactin; thus, the hypothalamus may be an important locus of endocrine malfunction in these patients. Levodopa 99-107 prolactin Homo sapiens 144-153 3086358-0 1986 Carbidopa plus L-dopa pretreatment inhibits the prolactin (PRL) response to thyrotropin-releasing hormone and thus cannot distinguish central from pituitary sites of prolactin stimulation. Levodopa 15-21 prolactin Homo sapiens 48-57 3086358-1 1986 Contrary to a previous report, pretreatment of normal men with carbidopa plus L-dopa (Sinemet 25/250) markedly inhibited the PRL response to TRH, a stimulus that acts directly on the pituitary. Levodopa 78-84 prolactin Homo sapiens 125-128 3086358-0 1986 Carbidopa plus L-dopa pretreatment inhibits the prolactin (PRL) response to thyrotropin-releasing hormone and thus cannot distinguish central from pituitary sites of prolactin stimulation. Levodopa 15-21 prolactin Homo sapiens 59-62 3870537-5 1985 Although the estrogen receptor assay is a fundamental procedure to know hormone dependency in breast cancer, the changes produced in the serum prolactin level after administering L-dopa is a simple and reproducible method that can be used as alternative predictive test in some cases. Levodopa 179-185 prolactin Homo sapiens 143-152 2424323-3 1986 Patients were given an overnight dexamethasone suppression test, and the effects of thyrotropin-releasing hormone and L-dopa on plasma growth hormone and prolactin were examined. Levodopa 118-124 prolactin Homo sapiens 154-163 3977547-2 1985 Serum prolactin (PRL) level was assessed after challenges with apomorphine hydrochloride, saline, dopamine hydrochloride, or levodopa-carbidopa (Sinemet) in 19 control and 38 chronic schizophrenic subjects. Levodopa 125-133 prolactin Homo sapiens 6-15 3921593-3 1985 On the contrary, levodopa administration was able to reduce PRL secretion in all the subjects studied. Levodopa 17-25 prolactin Homo sapiens 60-63 3870537-6 1985 This work shows that a 65 per 100 decrease or more in the L-dopa induced prolactin level prognosticates the existence of a hormone responsive tumor. Levodopa 58-64 prolactin Homo sapiens 73-82 6657127-1 1983 The changes in prolactin release induced by acute doses of L-Dopa + benserazide (250 mg) were analysed in Parkinson disease patients undergoing various drug treatments. Levodopa 59-65 prolactin Homo sapiens 15-24 6523351-1 1984 The authors studied the basal and L-DOPA-stimulated levels of STH and basal level of prolactin in blood serum of 128 patients presenting with acromegaly. Levodopa 34-40 prolactin Homo sapiens 85-94 6978249-2 1982 To evaluate the possible involvement of prolactin in the regulation of testosterone secretion during exercise, the influence of prolactin inhibition by oral L-dopa (1 g) pretreatment was also studied. Levodopa 157-163 prolactin Homo sapiens 128-137 6414103-7 1983 It is concluded 1) that even in hypophysectomized normoprolactinemic patients the circulating PRL may originate mainly from the residual tumor cells, and 2) that the sulpiride test is useful to detect the abnormalities of hypothalamo-pituitary axis in operated patients with PRL-secreting adenomas, whereas TRH, arginine, and L-dopa tests are less useful for such purposes. Levodopa 326-332 prolactin Homo sapiens 94-97 6413305-1 1983 The prolactin responses to an oral challenge of L-dopa (0.5 g) and bromocriptine (2.5 mg) were studied in 31 hyperprolactinemic females without radiological abnormalities of pituitary fossa, in 12 hyperprolactinemic patients with minor radiological evidence suggesting the presence of a pituitary adenoma and in 16 normal volunteers in the early puerperium with physiological hyperprolactinemia. Levodopa 48-54 prolactin Homo sapiens 4-13 6413305-4 1983 These results suggest that the L-dopa suppression test might serve as a reliable indicator to detect prolactin-secreting microadenomas in patients with persistent hyperprolactinemia and radiologically normal pituitary fossae. Levodopa 31-37 prolactin Homo sapiens 101-110 7130339-3 1982 Preoperatively, the PRL inhibitory responses to L-dopa cured, 4 .3 +/- 3.8%; uncured, 50.1 +/- 5.5% of baseline) was blunted by pretreatment with the decarboxylase inhibitor carbidopa (cured, 79.1 +/- 4.1%; uncured, 76.8 +/- 9.2%). Levodopa 48-54 prolactin Homo sapiens 20-23 7044409-0 1982 Inhibition of the renin--aldosterone axis and of prolactin secretion during pregnancy by L-dopa. Levodopa 89-95 prolactin Homo sapiens 49-58 6861440-3 1983 The highest dose was as effective as 500 mg L-dopa, although the duration of action was shorter, with a decrease to below 50% of basal PRL values in all patients. Levodopa 44-50 prolactin Homo sapiens 135-138 6889295-0 1983 [Effect of acute levodopa load on blood prolactin concentration in patients with thyroid diseases]. Levodopa 17-25 prolactin Homo sapiens 40-49 6889295-1 1983 In 14 thyrotoxic patients and 5 persons with endemic euthyroid goiter the blood plasma prolactin content was studied under the action of an acute oral load of levodopa in a dose of 0.5 g. It was found that the basal prolactin level was significantly higher in the blood of patients of both sexes with thyrotoxicosis and endemic euthyroid goiter than that in the control group (10 healthy humans). Levodopa 159-167 prolactin Homo sapiens 87-96 6889295-1 1983 In 14 thyrotoxic patients and 5 persons with endemic euthyroid goiter the blood plasma prolactin content was studied under the action of an acute oral load of levodopa in a dose of 0.5 g. It was found that the basal prolactin level was significantly higher in the blood of patients of both sexes with thyrotoxicosis and endemic euthyroid goiter than that in the control group (10 healthy humans). Levodopa 159-167 prolactin Homo sapiens 216-225 6889295-2 1983 The blood plasma prolactin content markedly decreased in thyrotoxic patients under levodopa effect, regardless of the sex, whereas in patients with endemic euthyroid goiter the drug exhibited no considerable action on the prolactin level. Levodopa 83-91 prolactin Homo sapiens 17-26 6401764-7 1983 Five patients responded with significant reduction in the serum hPRL concentration after L-dopa, and in three patients, no change was observed. Levodopa 89-95 prolactin Homo sapiens 64-68 6222183-4 1983 Following L-dopa, plasma prolactin concentrations decreased by greater than 50%, with the nadir noted within 90 minutes. Levodopa 10-16 prolactin Homo sapiens 25-34 6642424-6 1983 On the other hand, the administration of L-dopa resulted in a significant decrease in growth hormone level from 74.25 +/- 22 ng/ml (mean +/- SEM) at zero time to a level of 52.8 +/- 21 and 58.77 +/- 22.7 ng/ml at the 60- and 90-min intervals, respectively (p less than 0.05), and a significant decrease in prolactin level from a baseline of 56.18 +/- 17 to 25.5 +/- 8.4 ng/ml (p less than 0.001) at the 60-min interval. Levodopa 41-47 prolactin Homo sapiens 306-315 7102764-3 1982 In puerperal hyperprolactinemic subjects, the basal PRL (116.8 +/- 16.4 ng/ml) was suppressed 77% +/- 2% after administration of L-dopa and 51% +/- 7% after L-dopa plus carbidopa, significantly different from that of L-dopa alone (p less than 0.005), but similar to that observed in normal subjects. Levodopa 129-135 prolactin Homo sapiens 52-55 7102764-3 1982 In puerperal hyperprolactinemic subjects, the basal PRL (116.8 +/- 16.4 ng/ml) was suppressed 77% +/- 2% after administration of L-dopa and 51% +/- 7% after L-dopa plus carbidopa, significantly different from that of L-dopa alone (p less than 0.005), but similar to that observed in normal subjects. Levodopa 157-163 prolactin Homo sapiens 52-55 7102764-3 1982 In puerperal hyperprolactinemic subjects, the basal PRL (116.8 +/- 16.4 ng/ml) was suppressed 77% +/- 2% after administration of L-dopa and 51% +/- 7% after L-dopa plus carbidopa, significantly different from that of L-dopa alone (p less than 0.005), but similar to that observed in normal subjects. Levodopa 157-163 prolactin Homo sapiens 52-55 7102764-4 1982 In the patients with idiopathic hyperprolactinemia, the baseline PRL (131 +/- 38 ng/ml) decreased 56.3% after the administration of L-dopa. Levodopa 132-138 prolactin Homo sapiens 65-68 7102764-5 1982 In the presence of peripheral dopa decarboxylase inhibition, the administration of L-dopa decreased plasma PRL values 30%, a drop significantly different from that of L-dopa alone (p less than 0.02). Levodopa 83-89 prolactin Homo sapiens 107-110 7102764-8 1982 The increased pituitary sensitivity to L-dopa observed in puerperal women may be due to alterations in PRL receptors or vascularity. Levodopa 39-45 prolactin Homo sapiens 103-106 6807859-4 1982 Although L-dopa suppresses prolactin normally, the ability of thyrotropin releasing hormone (TRH) to stimulate the release of prolactin and thyroid stimulating hormone (TSH) is blunted. Levodopa 9-15 prolactin Homo sapiens 27-36 6278076-6 1982 However, prolactin levels were significantly lower in the Parkinsonian patients treated with levodopa versus the untreated group. Levodopa 93-101 prolactin Homo sapiens 9-18 7070643-0 1982 Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson"s disease. Levodopa 56-62 prolactin Homo sapiens 0-9 6978249-6 1982 Pharmacological blockade of prolactin release by L-dopa pretreatment failed to modify the response of testosterone to bicycle ergometer exercise. Levodopa 49-55 prolactin Homo sapiens 28-37 6810204-5 1981 Since the addition of carbidopa enhanced the suppression of prolactin induced by levodopa, exogenous levodopa probably acts predominantly through the formation of dopamine in the hypothalamus, but inside the blood-brain barrier, rather than as a direct effect of circulating dopamine on the anterior pituitary or areas of the hypothalamus outside the blood-brain barrier. Levodopa 81-89 prolactin Homo sapiens 60-69 6810204-3 1981 Levodopa elicited a normal suppression of prolactin concentrations in parkinsonian subjects; the major abnormality to emerge was attenuation of the response to thyrotropin-releasing hormone (TRH) in the parkinsonian patients following administration of Sinemet (levodopa plus carbidopa) or bromocriptine. Levodopa 0-8 prolactin Homo sapiens 42-51 6810204-5 1981 Since the addition of carbidopa enhanced the suppression of prolactin induced by levodopa, exogenous levodopa probably acts predominantly through the formation of dopamine in the hypothalamus, but inside the blood-brain barrier, rather than as a direct effect of circulating dopamine on the anterior pituitary or areas of the hypothalamus outside the blood-brain barrier. Levodopa 101-109 prolactin Homo sapiens 60-69 6785431-0 1981 Serum prolactin concentrations in mangabey (Cercocebus atys lunulatus) and patas (Erythrocebus patas) monkeys in response to stress, ketamine, TRH, sulpiride and levodopa. Levodopa 162-170 prolactin Homo sapiens 6-15 6790560-5 1981 Five hundred milligrams of L-dopa increased the GH level from 2.2 +/- 0.7 to 16.7 +/- 2.2 ng/ml in 60 min (P less than 0.002) and reduced the PRL level from 11.6 +/- 2.9 to 3.1 +/- 0.4 ng/ml in 150 min (P less than 0.05). Levodopa 27-33 prolactin Homo sapiens 142-145 6785431-8 1981 Oral administration of levodopa was followed by a significant fall in serum prolactin. Levodopa 23-31 prolactin Homo sapiens 76-85 6785431-11 1981 The variations in serum prolactin levels observed in these monkeys under the influence of stress, TRH, sulpiride and levodopa are similar to those observed in man to the same stimuli, although the experimental conditions were quite different. Levodopa 117-125 prolactin Homo sapiens 24-33 7226570-1 1980 It has been reported that administration of nomifensine (Nom) or of L-dopa + carbidopa (L-dopa + Carb) potentiates central dopaminergic tonus, resulting in decreased prolactin (PRL) secretion. Levodopa 68-74 prolactin Homo sapiens 177-180 6787839-9 1981 It is concluded that in subjects with sellar changes and intrasellar cisternal herniation ("empty sella"), and with moderate increases in PRL, the responses to TRH and L-dopa and to bromocriptine may help to differentiate between the empty sella syndrome and a coexisting pituitary tumour. Levodopa 168-174 prolactin Homo sapiens 138-141 7264625-6 1981 During chronic L-Dopa + carbidopa therapy, the basal PRL levels, evaluated in 21 PP, showed a correlation with the severity of clinical features. Levodopa 15-21 prolactin Homo sapiens 53-56 6777462-1 1980 Levodopa with carbidopa suppressed prolactin release induced by thyrotrophin releasing hormone less effectively in patients with idiopathic Parkinson"s disease than in normal subjects. Levodopa 0-8 prolactin Homo sapiens 35-44 7226570-1 1980 It has been reported that administration of nomifensine (Nom) or of L-dopa + carbidopa (L-dopa + Carb) potentiates central dopaminergic tonus, resulting in decreased prolactin (PRL) secretion. Levodopa 88-94 prolactin Homo sapiens 177-180 7226570-6 1980 PRL levels decreased in the normal controls below the basal values by 61.3% +/- 6.2 (SEM) after Nom and 77.6% +/- 4.2 after L-dopa + Carb. Levodopa 124-130 prolactin Homo sapiens 0-3 7226570-7 1980 Decreases in serum PRL of at least 50% (in three consecutive determinations) were found in group A in 20% of patients after Nom and in 25% after L-dopa + Carb; in group B in 15% and 40% of cases; in most of the hyperprolactinaemic women in group C; and some in group D. In conclusion, these two treatments did not discriminate between tumorous and non-tumorous cases of PRL hypersecretion. Levodopa 145-151 prolactin Homo sapiens 19-22 394552-2 1979 Serum levels of prolactin (PRL) were elevated pre-operatively and decreased after administration of L-Dopa with no increase after TRH as is usually observed in PRL-secreting adenomas. Levodopa 100-106 prolactin Homo sapiens 16-25 7357832-6 1980 Prolactin levels were equally suppressed by L-dopa and did not change after clonidine in either group. Levodopa 44-50 prolactin Homo sapiens 0-9 119396-2 1979 L-Dopa, but not atropine pre-treatment, attenuated the prolactin (PRL) response to MET. Levodopa 0-6 prolactin Homo sapiens 55-64 43786-2 1979 The serum prolactin response to cimetidine was abolished by dopamine infusion and almost completely suppressed by L-dopa plus carbidopa administration. Levodopa 114-120 prolactin Homo sapiens 10-19 112817-2 1979 It was found that in patients with pituitary adenoma the basal prolactin (PRL) level often exceeded 150 micrograms/l and the response to stimulation with TRH and/or metoclopramide was markedly diminished or even nonexistent, while the response to L-DOPA was usually retained. Levodopa 247-253 prolactin Homo sapiens 63-72 489713-4 1979 When pooling the results of the PRL-secreting adenomas, the mean levels of PRL with dopamine, L-dopa, and bromocriptine were, respectively, 49%, 55%, and 60% of the control levels. Levodopa 94-100 prolactin Homo sapiens 75-78 112817-0 1979 The effect of metoclopramide, TRH and L-dopa on prolactin secretion in pituitary adenoma and in "functional" galactorrhoea syndrome. Levodopa 38-44 prolactin Homo sapiens 48-57 112817-2 1979 It was found that in patients with pituitary adenoma the basal prolactin (PRL) level often exceeded 150 micrograms/l and the response to stimulation with TRH and/or metoclopramide was markedly diminished or even nonexistent, while the response to L-DOPA was usually retained. Levodopa 247-253 prolactin Homo sapiens 74-77 86882-6 1979 Prolactin response to the acute oral administration of L-dopa and bromocriptine was of less diagnostic value. Levodopa 55-61 prolactin Homo sapiens 0-9 103087-3 1978 L-DOPA and chlostylbegit were capable of reducing prolactin level in patients with the persisting lactorrhea-amenorrhea syndrome, this being accompanied by restoration of biphasic menstrual cycle in some of the patients. Levodopa 0-6 prolactin Homo sapiens 50-59 110148-3 1979 Prolactin levels responded to thyrotropin releasing hormone and L-dopa administration, but not chlorpromazine. Levodopa 64-70 prolactin Homo sapiens 0-9 288372-3 1979 Dopaminergic agonists (apomorphine, piribedil, d-amphetamine, L-DOPA, and the ergot derivatives bromocriptine and lisuride) all caused a decrease of serum prolactin levels. Levodopa 62-68 prolactin Homo sapiens 155-164 225167-4 1979 Suppression of plasma prolactin (PRL) by levodopa (l-dopa) was impaired and elevation of basal plasma PRL was noted at the second admission. Levodopa 41-49 prolactin Homo sapiens 22-31 225167-4 1979 Suppression of plasma prolactin (PRL) by levodopa (l-dopa) was impaired and elevation of basal plasma PRL was noted at the second admission. Levodopa 51-57 prolactin Homo sapiens 22-31 447211-0 1979 Cimetidine and L-dopa in the control of prolactin secretion in man. Levodopa 15-21 prolactin Homo sapiens 40-49 114343-4 1979 On the other hand, in the hyperprolactinaemic group, an impaired PRL response to TRH, Chlorpromazine and L-Dopa was noted in patients with basal PRL levels higher than 30 ng/ml, whereas bromocriptine suppressed effectively PRL levels in all the hyperprolactinaemic patients tested irrespective of their basal PRL concentrations. Levodopa 105-111 prolactin Homo sapiens 65-68 114343-4 1979 On the other hand, in the hyperprolactinaemic group, an impaired PRL response to TRH, Chlorpromazine and L-Dopa was noted in patients with basal PRL levels higher than 30 ng/ml, whereas bromocriptine suppressed effectively PRL levels in all the hyperprolactinaemic patients tested irrespective of their basal PRL concentrations. Levodopa 105-111 prolactin Homo sapiens 145-148 114343-4 1979 On the other hand, in the hyperprolactinaemic group, an impaired PRL response to TRH, Chlorpromazine and L-Dopa was noted in patients with basal PRL levels higher than 30 ng/ml, whereas bromocriptine suppressed effectively PRL levels in all the hyperprolactinaemic patients tested irrespective of their basal PRL concentrations. Levodopa 105-111 prolactin Homo sapiens 145-148 114343-4 1979 On the other hand, in the hyperprolactinaemic group, an impaired PRL response to TRH, Chlorpromazine and L-Dopa was noted in patients with basal PRL levels higher than 30 ng/ml, whereas bromocriptine suppressed effectively PRL levels in all the hyperprolactinaemic patients tested irrespective of their basal PRL concentrations. Levodopa 105-111 prolactin Homo sapiens 145-148 114343-5 1979 The ratio between the fall in PRL concentrations (as percent of the baseline) after L-Dopa administration (delta%L) versus the PRL decrement after bromocriptine treatment (delta%B) was calculated. Levodopa 84-90 prolactin Homo sapiens 30-33 45469-9 1978 These results suggest a dichotomy between the PRL and GH responses to combined L-dopa-carbidopa and dopamine agonist therapy. Levodopa 79-85 prolactin Homo sapiens 46-49 665840-1 1978 Prolactin levels were determined in plasma samples obtained before and after administration of apomorphine or L-dopa to otherwise unmedicated chronic schizophrenic patients or control subjects. Levodopa 110-116 prolactin Homo sapiens 0-9 709890-6 1978 Under chronic sulpiride-induced hyperprolactinaemia, levodopa exhibited however a very slight inhibitory effect on PRL concentrations. Levodopa 53-61 prolactin Homo sapiens 115-118 233660-4 1978 The ingestion of L-dopa 2 h before parathyroid hormone infusion suppressed the PRL response, suggesting that dopamine and parathyroid hormone interact at a common site. Levodopa 17-23 prolactin Homo sapiens 79-82 638883-4 1978 L-Dihydroxyphenylalanine (L-dopa) inhibited prolactin release from pituitaries in the presence of a hypothalamus but not in isolated pituitaries. Levodopa 0-24 prolactin Homo sapiens 44-53 675856-2 1978 The prolactin inhibition by the Levodopa was verified, and the clinical and mammographic growth, the doubling time, and the labeling index of the tumor were determined. Levodopa 32-40 prolactin Homo sapiens 4-13 656281-0 1978 The effect of low dose carbidopa/levodopa on prolactin and growth hormone concentrations in patients with breast cancer and in benign breast tumours. Levodopa 33-41 prolactin Homo sapiens 45-54 656281-3 1978 3 Prolactin and growth hormone showed similar responses to carbidopa/levodopa irrespective of age or diagnosis. Levodopa 69-77 prolactin Homo sapiens 2-11 659585-1 1978 The administration of l-dopa suppresses prolactin (PRL) secretion in normal subjects and in patients with hyperprolactinemia, although it is not known whether this effect, which requires the conversion of dopa to dopamine, is mediated peripherally or through the central nervous system. Levodopa 22-28 prolactin Homo sapiens 40-49 659585-1 1978 The administration of l-dopa suppresses prolactin (PRL) secretion in normal subjects and in patients with hyperprolactinemia, although it is not known whether this effect, which requires the conversion of dopa to dopamine, is mediated peripherally or through the central nervous system. Levodopa 22-28 prolactin Homo sapiens 51-54 659585-3 1978 Similar degrees of PRL suppression were observed in normal subjects (basal plasma PRL 13+/-2 ng/ml) after l-dopa alone (48+/-4%) and after l-dopa plus carbidopa (58+/-6%). Levodopa 106-112 prolactin Homo sapiens 19-22 659585-3 1978 Similar degrees of PRL suppression were observed in normal subjects (basal plasma PRL 13+/-2 ng/ml) after l-dopa alone (48+/-4%) and after l-dopa plus carbidopa (58+/-6%). Levodopa 139-145 prolactin Homo sapiens 19-22 659585-4 1978 In patients with pituitary tumors and elevated plasma PRL (73+/-14 ng/ml), l-dopa alone led to PRL suppression comparable with that in normal subjects (47+/-6%). Levodopa 75-81 prolactin Homo sapiens 54-57 659585-4 1978 In patients with pituitary tumors and elevated plasma PRL (73+/-14 ng/ml), l-dopa alone led to PRL suppression comparable with that in normal subjects (47+/-6%). Levodopa 75-81 prolactin Homo sapiens 95-98 659585-5 1978 However, l-dopa plus carbidopa resulted in only minimal suppression of plasma PRL (19+/-4%) which was significantly less than after l-dopa alone (P < 0.001). Levodopa 9-15 prolactin Homo sapiens 78-81 638883-4 1978 L-Dihydroxyphenylalanine (L-dopa) inhibited prolactin release from pituitaries in the presence of a hypothalamus but not in isolated pituitaries. Levodopa 26-32 prolactin Homo sapiens 44-53 566402-0 1978 [Changes induced with L-dopa in the serum levels of prolactin and somatotropin in the diagnosis of amenorrhea-galactorrhea]. Levodopa 22-28 prolactin Homo sapiens 52-61 23087-2 1978 Plasma prolactin increments to single doses of chlorpromazine, and prolactin decrements to single doses of levodopa, were similar in normal and schizophrenic subjects. Levodopa 107-115 prolactin Homo sapiens 67-76 562902-2 1977 Basal serum prolactin levels were raised, and were further elevated by the administration of L-dopa, chlorpromazine and TRH. Levodopa 93-99 prolactin Homo sapiens 12-21 591612-1 1977 In 6 normal subjects, L-dopa (500 mg PO) and apomorphine (0.6 mg sc) increased circulating growth hormone and suppressed prolactin levels in a parallel and quantitatively similar fashion, but only L-dopa induced a rise in plasma glucagon, glucose, and insulin levels. Levodopa 22-28 prolactin Homo sapiens 121-130 1024568-0 1976 [Effects of the treatment with an antiestrogen(tamoxifen) and levodopa on the secretion of prolactin in patients affected by breast cancer]. Levodopa 62-70 prolactin Homo sapiens 91-100 578618-5 1977 On the contrary, metergoline, like L-dopa, inhibited PRL release induced by pimozide pre-treatment. Levodopa 35-41 prolactin Homo sapiens 53-56 409726-9 1977 There was some suppression of prolactin levels after L-dopa. Levodopa 53-59 prolactin Homo sapiens 30-39 20170-0 1977 Dissociation of growth hormone and prolactin response to levodopa during pyridoxine administration. Levodopa 57-65 prolactin Homo sapiens 35-44 20170-1 1977 500 mg of levodopa was administered orally to 8 normal subjects and induced an increase of growth hormone (GH) and a decrease of prolactin (PRL) secretion. Levodopa 10-18 prolactin Homo sapiens 129-138 20170-1 1977 500 mg of levodopa was administered orally to 8 normal subjects and induced an increase of growth hormone (GH) and a decrease of prolactin (PRL) secretion. Levodopa 10-18 prolactin Homo sapiens 140-143 20170-2 1977 The levodopa-induced GH release was inhibited by an intravenous infusion of pyridoxine; on the contrary, the PRL response to levodopa was enhanced by pyridoxine infusion. Levodopa 125-133 prolactin Homo sapiens 109-112 20170-3 1977 This dissociation of GH and PRL responses to levodopa during pyridoxine infusion appears to be mediated by peripheral acceleration of the conversion of levodopa to dopamine. Levodopa 45-53 prolactin Homo sapiens 28-31 404308-8 1977 No significant suppression of serum PRL was seen in Group 2 patients given L-Dopa (500 mg orally),, which produced a significant response (P less than 0.05) in Group 1 subjects, while all patient showed marked reduction in serum PRL values following 2-bromo-alpha-ergocryptine (CB-154, 2.5 mg orally). Levodopa 75-81 prolactin Homo sapiens 229-232 406134-6 1977 Sulpiride treatment appeared to antagonize partially the inhibitory effect of L-dopa on prolactin release. Levodopa 78-84 prolactin Homo sapiens 88-97 556882-3 1977 Serum prolactin could be lowered with oral L-dopa. Levodopa 43-49 prolactin Homo sapiens 6-15 961756-1 1976 The time course of simultaneous changes in prolactin (PRL) and growth hormone secretion in response to a single dose of L-dopa and chlorpromazine was determined in normal women. Levodopa 120-126 prolactin Homo sapiens 43-52 961756-1 1976 The time course of simultaneous changes in prolactin (PRL) and growth hormone secretion in response to a single dose of L-dopa and chlorpromazine was determined in normal women. Levodopa 120-126 prolactin Homo sapiens 54-57 961756-3 1976 The PRL peak following chlorpromazine occurred at the same time as the nadir of PRL after L-dopa (3.5 hours). Levodopa 90-96 prolactin Homo sapiens 80-83 961756-4 1976 The quantity of PRL release inhibited by L-dopa equaled the amount of PRL secretion during the period of rebound, suggesting L-dopa inhibits PRL release, but not synthesis, by the pituitary. Levodopa 41-47 prolactin Homo sapiens 16-19 961756-4 1976 The quantity of PRL release inhibited by L-dopa equaled the amount of PRL secretion during the period of rebound, suggesting L-dopa inhibits PRL release, but not synthesis, by the pituitary. Levodopa 125-131 prolactin Homo sapiens 16-19 1000028-0 1976 Plasma prolactin response to L-dopa TRH and metaclopramide in thyrotoxicosis. Levodopa 29-35 prolactin Homo sapiens 7-16 562688-3 1977 Like levodopa, pyridoxine suppressed the increase in PRL secretion induced by treatment with pimozide, a specific dopamine receptor blocking agent. Levodopa 5-13 prolactin Homo sapiens 53-56 66455-0 1977 Growth hormone and prolactin response to levodopa in affective illness. Levodopa 41-49 prolactin Homo sapiens 19-28 402377-3 1977 Prolactin concentrations were increased by TRH and were suppressed by L-dopa. Levodopa 70-76 prolactin Homo sapiens 0-9 971016-4 1976 The only other, but most striking abnormality, was an excessively high serum prolactin level, which was partially suppressed with levodopa. Levodopa 130-138 prolactin Homo sapiens 77-86 7571-5 1976 Pretreatment with 500 mg of L-dopa suppressed the prolactin response to metoclopramide in 6 men to a mean response of 16.3 +/- 4.3 ng/ml. Levodopa 28-34 prolactin Homo sapiens 50-59 1000028-4 1976 This data suggests that, in thyrotoxicosis, PRl response to TRH only is impaired, but PRL can be suppressed by L-dopa or released by metaclopramide notwithstanding the elevated values of thyroid hormone levels. Levodopa 111-117 prolactin Homo sapiens 86-89 777023-4 1976 Pre-treatment with 500 mg L-dopa inhibited the early metoclopramide-induced prolactin increase, which is consistent with the possibility that metoclopramide acts by inhibiting dopamine-mediated hypothalamic secretion of prolactin inhibitory factor. Levodopa 26-32 prolactin Homo sapiens 76-85 777023-4 1976 Pre-treatment with 500 mg L-dopa inhibited the early metoclopramide-induced prolactin increase, which is consistent with the possibility that metoclopramide acts by inhibiting dopamine-mediated hypothalamic secretion of prolactin inhibitory factor. Levodopa 26-32 prolactin Homo sapiens 220-229 1020916-5 1976 Administration of L-Dopa (500 mg orally) significantly suppressed the prolactin values in the 11 cases studied. Levodopa 18-24 prolactin Homo sapiens 70-79 239963-5 1975 L-dopa significantly lowered basal plasma hPRL levels and also significantly blunted TRH-induced hPRL release. Levodopa 0-6 prolactin Homo sapiens 42-46 1206543-0 1975 Proceedings: The importance of intracerebral decarboxylation of L-DOPA in the suppression of prolactin secretion. Levodopa 64-70 prolactin Homo sapiens 93-102 174362-0 1976 Suppressive effect of L-dopa on human prolactin release during sleep. Levodopa 22-28 prolactin Homo sapiens 38-47 1095122-2 1975 L-Dopa lowers plasma prolactin levels, and there have been reports that patients with advanced breast cancer have been successfully treated with L-dopa. Levodopa 0-6 prolactin Homo sapiens 21-30 239963-5 1975 L-dopa significantly lowered basal plasma hPRL levels and also significantly blunted TRH-induced hPRL release. Levodopa 0-6 prolactin Homo sapiens 97-101 4632690-1 1973 Prolactin secretion was assessed in 23 patients with hypothalamic-pituitary disorders using L-Dopa suppression, chlorpromazine (CPZ), and thyrotropin-releasing hormone (TRH) stimulation tests. Levodopa 92-98 prolactin Homo sapiens 0-9 1172495-0 1975 Spontaneous diurnal variations of serum prolactin and prolactin response to L-dopa in man. Levodopa 76-82 prolactin Homo sapiens 54-63 1168655-5 1975 L-Dopa suppression of serum PRL was not significantly influenced by T4 in these patients. Levodopa 0-6 prolactin Homo sapiens 28-31 1168856-7 1975 L-Dopa produced appropriate suppression of serum PRL concentrations in the normals and both patient groups. Levodopa 0-6 prolactin Homo sapiens 49-52 4356808-0 1973 Growth hormone and prolactin in unipolar and bipolar depressed patients: responses to hypoglycemia and L-dopa. Levodopa 103-109 prolactin Homo sapiens 19-28 4196300-0 1973 [Effect of L-Dopa on the secretion of prolactin in eels]. Levodopa 11-17 prolactin Homo sapiens 38-47 4630270-0 1973 Suppression of serum thyrotropin (TSH) by L-dopa in chronic hypothyroidism: interrelationships in the regulation of TSH and prolactin secretion. Levodopa 42-48 prolactin Homo sapiens 124-133 5107027-0 1971 Levodopa suppression of prolactin in nonpuerperal galactorrhea. Levodopa 0-8 prolactin Homo sapiens 24-33 4622109-4 1972 L-Dopa (D,L-alpha-hydrazino-alpha-methyl-beta-[3,4-di-hydroxyphenyl]) has the opposite effect; it inhibits prolactin secretion and may be effective in suppressing galactorrhea. Levodopa 0-6 prolactin Homo sapiens 107-116